Ofer Haviv
Chief Executive Officer bij EVOGENE LTD.
Vermogen: - $ op 31-03-2024
Profiel
Ofer Haviv is currently the President & Chief Executive Officer at Evogene Ltd., Chairman at Evofuel Ltd., Chairman at Evogene, Inc., Chairman at Lavie Bio Ltd., and Chairman at Biomica Ltd.
He previously worked as the Treasurer & Finance Director at Compugen Ltd.
Mr. Haviv completed his undergraduate degree at Tel-Aviv University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
EVOGENE LTD
-.--% | 17-03-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Ofer Haviv
| Bedrijven | Functie | Begin |
|---|---|---|
| EVOGENE LTD. | Chief Executive Officer | 01-12-2004 |
| Evofuel Ltd. | Chairman | 01-01-2012 |
| Evogene, Inc. | Chairman | 01-01-2006 |
Biomica Ltd.
 Biomica Ltd. Miscellaneous Commercial ServicesCommercial Services Biomica Ltd. engages in the provision of biopharmaceutical services. Its technology focuses on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. The company was founded by Yehuda Ringel in 2017 and is headquartered in Rehovot, Israel. | Chairman | - |
| Lavie Bio Ltd. | Chairman | - |
Eerdere bekende functies van Ofer Haviv
| Bedrijven | Functie | Einde |
|---|---|---|
| COMPUGEN LTD. | Director of Finance/CFO | - |
Opleiding van Ofer Haviv
| Tel-Aviv University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| COMPUGEN LTD. | Health Technology |
| EVOGENE LTD. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
| Evofuel Ltd. | |
| Evogene, Inc. | |
| Lavie Bio Ltd. | |
Biomica Ltd.
Biomica Ltd. Miscellaneous Commercial ServicesCommercial Services Biomica Ltd. engages in the provision of biopharmaceutical services. Its technology focuses on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. The company was founded by Yehuda Ringel in 2017 and is headquartered in Rehovot, Israel. | Commercial Services |
